Stoke Therapeutics, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 12.40M8.78M36.55M
Gross Profit 12.40M8.78M36.55M
Operating items
Research & Development 77.84M82.23M89.13M
Selling, General & Administrative 38.92M41.32M48.79M
Operating Expenses 116.76M123.55M137.93M
Operating Income -104.36M-114.77M-101.37M
EBIT -104.36M-114.77M-101.37M
Non-operating items
Interest & Investment Income 3.12M9.91M12.64M
Other Non Operating Income 0.17M0.17M-0.25M
Non Operating Income 3.29M10.07M12.39M
Net income details
EBT -101.23M-104.86M-88.73M
Profit After Tax -101.07M-104.70M-88.98M
Income from Continuing Operations -101.23M-104.86M-88.73M
Consolidated Net Income -101.23M-104.86M-88.73M
Income towards Parent Company -101.23M-104.86M-88.73M
Net Income towards Common Stockholders -101.23M-104.86M-88.73M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 30.27M32.73M33.47M36.79M39.43M44.65M52.97M
Shares Outstanding (Diluted Average) 38.90M43.99M54.01M
EBITDA -102.07M-103.55M-89.11M
Shares Outstanding 39.44M45.92M54.03M